President Joe Biden said Friday that he is planning to request more money from Congress to develop another new coronavirus vaccine, as scientists track new waves and hospitalizations rise, though not like before.
Officials are already expecting updated COVID-19 vaccines that contain one version of the omicron strain, called XBB.1.5. It's an important change from today's combination shots, which mix the original coronavirus strain with last year's most common omicron variants. But there will always be a need for updated vaccines as the virus continues to mutate.
It's not clear exactly when people can start rolling up their sleeves for what officials hope is an annual fall COVID-19 shot. Pfizer, Moderna and smaller manufacturer Novavax all are brewing doses of the XBB update but the Food and Drug Administration will have to sign off on each, and the U.S. Centers for Disease Control and Prevention must then issue recommendations for their use.
I signed off this morning on a proposal we have to present to the Congress a request for additional funding for a new vaccine that is necessary, that works, Biden, who is vacationing in the Lake Tahoe area, told reporters on Friday.
He added that it's tentatively recommended that everybody get it, once the shots are ready.
The White House's $40 billion funding request to Congress on Aug. 11 did not mention COVID-19. It included funding requests for Ukraine, to replenish U.S. federal disaster funds at home after a deadly climate season of heat and storms, and funds to bolster the enforcement at the Southern border with Mexico, including money to curb the flow of deadly fentanyl. Last fall, the administration asked for $9.25 billion in funding to combat the virus, but Congress refused the request.
For the week ending July 29, COVID-19 hospital admissions were at 9,056. That's an increase of about 12% from the previous week. But it's a far cry from past peaks, like the 44,000 weekly hospital admissions in early January, the nearly 45,000 in late July 2022, or the 150,000 admissions during the omicron surge of January 2022.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)